Afobazol tab.
Category
Sedatives
,
Antipsychotics
,
Neurological disorders
Scope of the medicinal product
General
Release form
Tablet
Manufacturer country
Russia
Package quantity, pcs
60
Dosage form
pills
Manufacturer
Pharmstandard, Russia
Structure
1 tablet contains:
active substance: fabomotizol (fabomotizole dihydrochloride) - 10 mg.
auxiliary substances: potato starch - 48 mg, microcrystalline cellulose - 35 mg, lactose monohydrate - 48.5 mg, medium molecular weight povidone (medium molecular weight polyvinylpyrrolidone, Kollidon 25) - 7 mg, magnesium stearate - 1.5 mg.
pharmachologic effect
Pharmacodynamics
Afobazole is a selective non-benzodiazepine anxiolytic.
Acting on sigma-1 receptors in the nerve cells of the brain, Afobazol stabilizes GABA / benzodiazepine receptors and restores their sensitivity to endogenous mediators of inhibition.
Afobazole also increases the bioenergetic potential of nerve cells and protects them from damage (has a neuroprotective effect).
The effect of the drug is realized mainly in the form of a combination of anxiolytic (anti-anxiety) and mild stimulating (activating) effects. Afobazole reduces or eliminates feelings of anxiety (concern, bad feelings, apprehension, irritability), tension (fearfulness, tearfulness, anxiety, inability to relax, insomnia, fear), somatic manifestations of anxiety (muscle, sensory, cardiovascular, respiratory, gastrointestinal intestinal symptoms), autonomic disturbances (dry mouth, sweating, dizziness), cognitive disorders (difficulty concentrating, impaired memory). The use of the drug is especially shown in persons with predominantly asthenic personality traits in the form of anxious suspiciousness, uncertainty, increased vulnerability and emotional lability,tendency to emotionally stressful reactions.
The effect of the drug develops on the 5-7th day of treatment.
The maximum effect is achieved by the end of 4 weeks of treatment and remains after the end of treatment for an average of 1-2 weeks.
Afobazole causes muscle weakness, drowsiness, and has no negative effect on concentration and memory.
When using it, drug dependence is not formed and the withdrawal syndrome does not develop.
Pharmacokinetics
After oral administration, Afobazol is well and rapidly absorbed from the gastrointestinal tract.
The maximum concentration of the drug in plasma (Cmax) is 0.130 + 0.073 μg / ml
the time to reach the maximum concentration (Tmax) - 0.85 + 0.13 hours.
Metabolism: Afobazol undergoes a first pass effect" through the liver, the main directions of metabolism are hydroxylation at the aromatic ring of the benzimidazole cycle and oxidation at the morpholine fragment.
Afobazole is intensively distributed over well-vascularized organs, it is characterized by rapid transfer from the central pool (blood plasma) to the peripheral (highly vascularized organs and tissues).
The half-life of Afobazol when taken orally is 0.82 + 0.54 hours.
The short half-life is due to the intensive biotransformation of the drug and the rapid distribution from blood plasma to organs and tissues.
The drug is excreted mainly in the form of metabolites and partially unchanged in the urine and feces.
Indications
Afobazol is used in adults with anxiety conditions:
generalized anxiety disorders,
neurasthenia,
adjustment disorders,
in patients with various somatic diseases (bronchial asthma, irritable bowel syndrome, systemic lupus erythematosus, ischemic heart disease, hypertension, arrhythmias),
dermatological, oncological and other diseases.
In the treatment of sleep disorders associated with anxiety, neurocirculatory dystonia, premenstrual syndrome, alcohol withdrawal syndrome, to alleviate the withdrawal syndrome in smoking cessation.
Contraindications
Individual intolerance to the drug Afobazol.
Galactose intolerance, lactase deficiency or glucose-galactose malabsorption.
Pregnancy, lactation.
Children under the age of 18.
Side effects
Allergic reactions are possible.
Rarely - headache, which usually goes away on its own and does not require discontinuation of the drug.
Interaction
Afobazol does not interact with ethanol and does not affect the hypnotic effect of thiopental.
Enhances the anticonvulsant effect of carbamazepine.
Increases the anxiolytic effect of diazepam.
How to take, course and dosage
It is applied orally, after meals.
The optimal single dose is 10 mg
daily allowance - 30 mg, divided into 3 doses during the day.
The duration of the course of the drug is 2-4 weeks.
If necessary, on the recommendation of a doctor, the daily dose of the drug can be increased to 60 mg, and the duration of treatment up to 3 months.
Overdose
With a significant overdose and intoxication, the development of a sedative effect and increased drowsiness is possible without manifestations of muscle relaxation.
As an emergency, caffeine 20% solution is used in ampoules of 1.0 ml 2-3 times a day subcutaneously.
Special instructions
The drug does not have a negative effect on driving vehicles and performing potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.
Release form
Pills
Storage conditions
In a dry, dark place at a temperature not exceeding 25 ° C
Shelf life
2 years
Brand name
AFOBAZOLE
Active substance
Morpholinoethylthioethoxybenzimidazole
Terms of dispensing from pharmacies
Without recipe
Name ENG
AFOBAZOL
Clinical and pharmacological group
Anxiolytic (tranquilizer)
ATX code
Fabomotizole
Dosage
10mg
Structure
1 tablet contains: active ingredient: fabomotizol (fabomotizole dihydrochloride) - 10 mg auxiliary substances: potato starch - 48 mg, microcrystalline cellulose - 35 mg, lactose monohydrate - 48.5 mg, medium molecular weight povidone (polyvinylpyrrolidone 25 med. ) - 7 mg, magnesium stearate - 1.5 mg.
Indications
Anxiety in adults:
generalized anxiety disorders, neurasthenia, adjustment disorders
in patients with various somatic (bronchial asthma, irritable bowel syndrome, SLE, ischemic heart disease, arterial hypertension, arrhythmias), dermatological, oncological and other diseases
sleep disorders associated with anxiety
cardiopsychoneurosis
premenstrual tension syndrome
alcohol withdrawal syndrome
to alleviate smoking cessation symptoms.
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 3 years
Contraindications
pregnancy
,
lactation period (breastfeeding)
age up to 18 years
hypersensitivity to the components of Afobazole.
INN / Active ingredient
Fabomotizol
Specifications
Category
Sedatives
,
Antipsychotics
,
Neurological disorders
Scope of the medicinal product
General
Release form
Tablet
Manufacturer country
Russia
Package quantity, pcs
60
Vacation conditions
Without recipe
Brand name
OTCPharm
The amount of the dosage form in the primary package
30 pcs.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Anxiolytic agent (tranquilizer)
Anatomical and therapeutic characteristics
N05BX Other Anxiolytics
Dosage form
Pills
Expiration date in days
1095
Dosage (volume) of the substance in the preparation
fabomotizole (fabomotizole dihydrochloride) - 10 mg
Package weight, g
twenty
Mode of application
:
It is applied orally, after meals. < br> < br> Optimal single doses - 10 mg
daily allowance - 30 mg, divided into 3 doses during the day.
The duration of the course of use of the drug is 2-4 weeks. < br> < br> If necessary, on the recommendation of a doctor, the daily dose of the drug can be increased to 60 mg, and the duration of treatment up to 3 months.
Information on technical characteristics, delivery set, country of manufacture "